-+ 0.00%
-+ 0.00%
-+ 0.00%

BGF joins T-Therapeutics’ $133 million Series B funding round

PUBT·11/05/2026 09:18:51
Listen to the news
BGF joins T-Therapeutics’ $133 million Series B funding round
  • BGF completed a follow-on investment in T-Therapeutics’ oversubscribed $133 million Series B round, announced November 5, 2026.
  • T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases.
  • Advent Life Sciences and British Business Bank co-led the financing, with participation from new investors and existing major shareholders.
  • Proceeds will fund clinical development and proof-of-concept data for two lead programs targeting solid tumors and chronic tissue inflammation.
  • The investment follows BGF’s initial backing in November 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BGF Investment Management Ltd published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.